Navigation Links
Afinitor (Breast Cancer) - Analysis and Forecasts to 2020
Date:10/20/2011

tic Breast Cancer 27

Figure 33: Drug Model Diagram of Afinitor in the US, EU and Japan 33

Figure 34: Afinitor, Breast Cancer, Global, Sales Forecasts ($m), 2013–2020 35

Figure 35: Afinitor, Breast Cancer, the US, Sales Forecasts ($m), 2013–2020 36

Figure 36: Afinitor, Breast Cancer, the UK, Sales Forecasts ($m), 2013–2020 37

Figure 37: Afinitor, Breast Cancer, France, Sales Forecasts ($m), 2013–2020 38

Figure 38: Afinitor, Breast Cancer, Germany, Sales Forecasts ($m), 2013–2020 39

Figure 39: Afinitor, Breast Cancer, Italy, Sales Forecasts ($m), 2013–2020 40

Figure 40: Afinitor, Breast Cancer, Spain, Sales Forecasts ($m), 2013–2020 41

Figure 41: Afinitor, Breast Cancer, Japan, Sales Forecasts ($m), 2013-2020 42

Figure 42: Afinitor, Breast Cancer, Global, Sales Distribution by Country ($m), 2020 43

Figure 43: Drug Model Diagram 46

Figure 44: Patients Approved to take the Drug 47

To order this report:

Pathology Industry: Afinitor (Breast Cancer) – Analysis and Forecasts to 2020

Pathology Business News

More  Industry Analysis and Insights

CONTACT
Nicolas Bombourg
Reportlinker
Email: nbo@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626


'/>"/>
SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Novartis Drug Afinitor® Effective in Patients With Non-Cancerous Kidney Tumors Associated With TSC in Phase III Trial
2. Phase III Trial of Novartis Drug Afinitor® Met Primary Endpoint of Reducing SEGA Tumor Size in Patients With Tuberous Sclerosis
3. FDA Approves Novartis Drug Afinitor to Treat Pancreatic Neuroendocrine Tumors
4. Novartis Gains FDA Approval for Afinitor® as First New Treatment in Nearly Three Decades for Patients with Advanced Pancreatic NET
5. Novartis Drug Afinitor® Recommended by FDA Oncology Advisory Committee for Approval to Treat Advanced NET of Pancreatic Origin
6. Study Shows Novartis Drug Afinitor® Plus Hormonal Therapy Delays Disease Progression in Advanced Metastatic Breast Cancer Patients
7. Study in NEJM Shows Novartis Drug Afinitor® Reduces Size of SEGAs, Benign Brain Tumors Associated with Tuberous Sclerosis
8. FDA Approves New Indication for Afinitor
9. VIDEO from thenewsmarket.com and Novartis: Novartis drug Afinitor® Approved by FDA as First Medication for Children and Adults With a Benign Brain Tumor Associated With Tuberous Sclerosis
10. Pivotal Phase III Trial of Novartis Drug Afinitor® Met Primary Endpoint in Study of Patients With Advanced Pancreatic Neuroendocrine Tumors
11. Afinitor(R) Phase II Data Show Positive Results for Patients With Multiple Types of Lymphoma, Leading to Phase III Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... 24, 2014  The International Trade Commission (ITC) issued its ... BMC Medical. In a notice issued on December 23, the ... patent on its humidifier was invalid. BMC President, ... "We are very excited with the ITC,s decision in this ... have taken since the very beginning on the key patents ...
(Date:12/24/2014)... 2014 PuraMed BioScience®, Inc., (OTC Pink: PMBS), ... and healthcare products, announced it received the initial funding ... advanced headache relief product, for planned distribution to 1,000 ... , Washington State , and ... MigraPure H Advanced headache relief gel formulation completed, PuraMed ...
(Date:12/24/2014)... 2014   Synageva BioPharma Corp. (NASDAQ: ... therapeutic products for rare disorders, today announced validation ... Marketing Authorization Application (MAA) for sebelipase alfa for ... request for accelerated assessment, which has the potential ... The MAA, and the Biologics License ...
Breaking Medicine Technology:ITC Final Decision Goes Against ResMed (RMD) Monumental Win for 3B/BMC 2PuraMed BioScience Nears Final Stages Needed for Distribution of MigraPure H 2PuraMed BioScience Nears Final Stages Needed for Distribution of MigraPure H 3Synageva BioPharma Announces Sebelipase Alfa Marketing Authorization Application Validated By The EMA 2Synageva BioPharma Announces Sebelipase Alfa Marketing Authorization Application Validated By The EMA 3
... , , FRAZER, Pa., Jan. 8 Cephalon, Inc., (Nasdaq: ... Robert P. Roche, Jr., Executive Vice President of Worldwide Pharmaceutical ... other longstanding interests. During his tenure, Mr. Roche established ... global business that exceeded $2 billion in annual sales revenue. ...
... , RIDGEWOOD, N.J., Dec. 31 Women,s Digital Imaging of ... a technology developed to screen for osteoporosis (bone loss), to ... method of establishing goals and measuring results for weight management ... been a standard measuring tool, it does not distinguish muscle ...
Cached Medicine Technology:Cephalon Executive Vice President of Worldwide Pharmaceutical Operations Robert Roche to Resign Position 2Cephalon Executive Vice President of Worldwide Pharmaceutical Operations Robert Roche to Resign Position 3Cephalon Executive Vice President of Worldwide Pharmaceutical Operations Robert Roche to Resign Position 4Women's Digital Imaging Using DXA Total Body Fat Analysis to Help Patients in Weight Management and Fitness Programs 2
(Date:12/25/2014)... York (PRWEB) December 25, 2014 Product ... DePuy ASR hip recall ( http://www.consumerinjurylawyers.com/DePuy/ ) continue to ... According to an Order issued in the U.S. District ... Court will convene an open conference on January 7, ... United States Courthouse in West Palm Beach, Florida. The ...
(Date:12/25/2014)... 2014 The short film “Color of Honor” ... honor of a true 9/11 hero, Welles Remy Crowther. It ... the 24 hours of Nuremberg International Short Film Festival and ... Actress, screenwriter and director Luciana Lagana plays the ... with her husband, Gregory Graham - Graham plays ...
(Date:12/25/2014)... When head lice hits a home or school, parents ... rid of it while keeping it from taking over the ... the solution right in their neighborhood: Lice Troopers . ... full spectrum head lice screening and treatment services to families ... Biscayne, Brickell, Coconut Grove, Kendall, Pinecrest and South Miami. , ...
(Date:12/25/2014)... News) -- Overeating is common during the holidays, but there ... expert says. "Don,t arrive at a party hungry. It ... you,ll be attending a party, but deprivation leads to hunger, ... Northern Westchester Hospital in Mount Kisco, N.Y., said in a ... the day and even to have a snack before attending ...
(Date:12/25/2014)... York, New York (PRWEB) December 25, 2014 ... ) continue to move forward in a number of ... District of West Virginia, Bernstein Liebhard LLP reports. According ... Court is scheduled to convene a Joint Status Conference ... at 10:00 a.m. Parties have been directed to submit ...
Breaking Medicine News(10 mins):Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 3Health News:The True 9/11 Hero Story “Color of Honor” Premieres in Germany and Bangladesh: Luciana Lagana Plays the Mother of the Lead and Co-Produces with Blaise Dolcemaschio. 2Health News:The True 9/11 Hero Story “Color of Honor” Premieres in Germany and Bangladesh: Luciana Lagana Plays the Mother of the Lead and Co-Produces with Blaise Dolcemaschio. 3Health News:Coral Gables Florida Gets Ready to Be Lice-Free with Lice Troopers 2Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 3Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 4
... 18 PROLOR Biotech, Inc., (OTC Bulletin Board: PBTH), ... that it has raised $24.4 million in a ... value $0.00001 per share, to accredited investors at ... an approximate 17% discount to the average closing price of ...
... FREMONT, Calif. , March 18 Velos, Inc., the recognized ... Kamar Aulakh has joined the company to serve as Chief Operating ... in technology and healthcare. In his role as COO, he will oversee all ... ...
... ... AIDS Foundation today announced that Dr Megan Dunbar has been appointed ... 5. Pangaea Global AIDS Foundation helps countries, heavily affected by ... with a particular focus on hard-to-reach vulnerable populations, including women and ...
... ClinAudits, ... quality remediation solutions for the pharmaceutical, medical device, biotechnology, and tissue engineering industries, announced ... , ... (PRWEB) March 18, 2010 -- ClinAudits , LLC, an independent, 3rd party ...
... that blocking a certain protein can reduce or ... underlies the disease process of chronic obstructive pulmonary ... The findings have been published online ahead ... American Journal of Respiratory and Critical Care ...
... ST. LOUIS , March 17 Centene Corporation (NYSE: CNC ) announced today that one of its subsidiaries, Cenpatico Behavioral Health of Arizona (Cenpatico), ... ... ... ...
Cached Medicine News:Health News:PROLOR Biotech Announces Sale of $24.4 Million of Common Stock 2Health News:PROLOR Biotech Announces Sale of $24.4 Million of Common Stock 3Health News:PROLOR Biotech Announces Sale of $24.4 Million of Common Stock 4Health News:Kamar Aulakh Joins Velos, Inc. as Chief Operating Officer 2Health News:Kamar Aulakh Joins Velos, Inc. as Chief Operating Officer 3Health News:Kamar Aulakh Joins Velos, Inc. as Chief Operating Officer 4Health News:Megan Dunbar Named VP of Programs for Pangaea Global AIDS Foundation 2Health News:ClinAudits Joins Bioanalytical Quality Standards Initiative (BQSI) Expert Working Group 2Health News:ClinAudits Joins Bioanalytical Quality Standards Initiative (BQSI) Expert Working Group 3Health News:New technique reduces tobacco smoke damage to lungs in mice 2Health News:Centene's Arizona Behavioral Health Unit Awarded Expanded Contract 2Health News:Centene's Arizona Behavioral Health Unit Awarded Expanded Contract 3Health News:Centene's Arizona Behavioral Health Unit Awarded Expanded Contract 4
... latest 3-part differential analyzer based on the ... the CELL-DYN line. Offering 18 parameters and ... CELL-DYN 1800 meets the needs to today's ... than its predecessors and fits under standard ...
... produces high-quality blood films. Smearing parameters have ... time, eliminating the need to make adjustments ... hematocrit values. In the closed sampling mode, ... and aspirates only 200L. Only 30L of ...
... InstaCheck® Menopause Predictor Test is an in ... FSH in urine. Changes in FSH levels ... symptoms associated with stages of menopause. The ... obtain a visual, qualitative result and is ...
... diabetes continue to have a tremendous impact ... of patients, in addition to the significant ... be associated with elevated levels of blood ... haemoglobin A1c (HbA1c) in a diabetic patient's ...
Medicine Products: